Please login to the form below

Not currently logged in

Novavax starts first phase 3 COVID-19 vaccine trial in the UK

Trial is set to enrol up to 10,000 participants aged 18-84

Almost a month after initiating the phase 2 portion of its COVID-19 vaccine trial in the US and Australia, Novavax has launched its first phase 3 trial in the UK.

The planned phase 3 study, which is being conducted in partnership with the UK government’s Vaccine Taskforce, will evaluate the efficacy, safety and immunogencity of Novavax’s COVID-19 vaccine, NVX-CoV2373.

The company is expecting to enrol and immunise up to 10,000 individuals aged between 18-84, with and without relevant comorbidities, over the next four to six weeks. Participants will either receive two intramuscular injections of Novavax’s vaccine and Matrix-M adjuvat, or a placebo shot.

The trial will aim to enrol at least 25% of participants over the age of 65, as well as give priority to groups that have been the most affected by COVID-19, including certain racial and ethnic minorities.

“The data from this trial is expected to support regulatory submissions for licensure in the UK, EU and other countries,” said Gregory Glenn, president, research and development at Novavax.

“We are grateful for the support of the UK Government, including from its Department of Health and Social Care and National Institute for Health Research, to advance this important research,” he added,

In a phase 1 study of Novavax’s vaccine candidate, the shot produced high levels of antibodies against the SARS-CoV-2 virus, which causes COVID-19, after a single dose of the vaccine.

Participants treated with NVX-CoV2373 also demonstrated higher levels of antibodies after two doses compared the levels seen in recovered COVID-19 patients. The addition of its Matrix-M adjuvant also boosted the effect of the vaccine in the early stage study, Novavax reported.

Novavax has been awarded $1.6bn by the US government under the Operation Warp Speed scheme to accelerate the research and development of its vaccine candidates. Under the terms of the deal, Novavax will produce 100 million doses of its vaccine by the beginning of 2021, if it continues to prove effective in further clinical studies.

The UK government also signed a deal with Novavax in August, which led to the phase 3 clinical trial, and has also partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components of the vaccine in the UK.

Article by
Lucy Parsons

25th September 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...